SCHEMBL19995071

SCHEMBL19995071

CC1(C)CCC(NS(=O)(=O)c2ccc(Br)c(Cl)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
TP53 P04637 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
LMNA P02545 1/20 0.45
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
HTT P42858 1/20 0.43
KDM4E B2RXH2 1/20 0.43
RECQL P46063 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29498633 1.00 MAPK1 (0.48) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL29498511 0.90 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19667873 0.90 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL17847655 0.90 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19667871 0.90 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19994862 0.84 ALDH1A1 (0.55) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL29498527 0.84 ALDH1A1 (0.55) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL21407132 0.81 KMT2A (0.49) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL29498518 0.81 KMT2A (0.49) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19995179 0.81 KMT2A (0.49) MAPK1SMN1; SMN2POLBTP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515913-B1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2022-05-11 EP disclosed
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2021-12-21 US disclosed
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-06-24 US disclosed
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2020-09-08 US disclosed
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2019-10-03 US disclosed
EP-3515913-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
WO-2018055551-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, TIMP3, ALPI MAPK1 1575/4885SMN1; SMN2 1935/4885POLB 2577/4885
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, TIMP3, ALPI MAPK1 1575/4885SMN1; SMN2 1935/4885POLB 2577/4885
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, ALPI, TIMP3 MAPK1 1614/4885SMN1; SMN2 1763/4885POLB 2469/4885
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, ALPI, TIMP3 MAPK1 1614/4885SMN1; SMN2 1763/4885POLB 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.